An expert medical panel discuss the nature of cancer research, and attempt to find the truth. David Agus, Donald Abrams, Michele Norris, Niven R. Narain, Ralph Moss, Shimon Slavin are in conversation. Location: Paepcke Auditorium"
Dr. Donald I. Abrams is a cancer and integrative medicine specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion. Abrams provides integrative medicine consultations for cancer patients and has completed research in complementary and alternative therapies including mind-body treatments, botanical therapies, medical use of marijuana and traditional Chinese medicine herbal therapies.
In addition to his role at the Osher center, he is chief of Hematology and Oncology at San Francisco General Hospital. Abrams, who has been in the forefront of HIV/AIDS research and treatment, stepped down from the HIV Clinic at San Francisco General Hospital in August 2006 to devote more time to integrative medicine and oncology. He is an executive committee member of the UCSF Helen Diller Family Comprehensive Cancer Center and is co-chair of of the center's program in Symptom Management, Palliative Care and Survivorship. In 2004, he completed an associate fellowship in integrative medicine at the University of Arizona.
Dr. David B. Agus
David Agus is one of the world’s top cancer doctors and a pioneer in new technologies for personalized health care. A professor at USC, with appointments in both the Keck School of Medicine and the Viterbi School of Engineering, he also heads the university’s Westside Cancer Center and the Center for Applied Molecular Medicine. He has cofounded several businesses, including the genetic testing company Navigenics and Oncology.com. He is also a cofounder of Applied Proteomics, which aims to tap the tremendous wealth of information contained in the body’s proteome—the complete set of all proteins circulating in the bloodstream—for earlier diagnosis of disease. Agus is a CBS News contributor and author of the number one New York Times best seller The End of Illness. His new book, A Short Guide to a Long Life, will be published in January 2014.
Ralph W. Moss is the author of twelve books and three documentaries about cancer. His most recent book, Customized Cancer Treatment, is the first study of chemosensitivity and resistance assays. His articles have recently appeared in the journals Immunbiology, Lancet online, and Pharmacological Research. For the past 35 years he has independently evaluated various cancer treatments. He directs The Moss Reports, writes a column for The Townsend Letter, and edits the online newsletter Advances in Cancer Treatment. Moss was a science writer at Memorial Sloan-Kettering Cancer Center from 1974 to 1977.
Niven R. Narain is co-founder, president, and chief technology officer of Berg Pharma, which focuses its research on understanding how alterations in metabolism relate to disease onset. His passion is innovation that drives patient care and the generation of actionable biological data. He discovered BPM 31510, the novel cancer drug in late stage clinical development for skin cancers and solid tumors. Most notably, Narain developed the Interrogative Biology platform, which uses core biological modeling to develop safe, effective drugs in a cost-effective manner. He has over 160 issued and pending patents and was director of cutaneous oncology at the University of Miami Miller School of Medicine. Narain is committed to changing the paradigm of innovation in medicine.
Michele Norris is one of the most respected voices in American journalism. As NPR host and special correspondent, Norris produces in-depth profiles, interviews and series, and guest hosts NPR News programs.
Shimon Slavin is professor of medicine and medical and scientific director of the International Center for Cell Therapy and Cancer Immunotherapy in Tel Aviv, Israel. Slavin pioneered the use of immunotherapy mediated by donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and more recently, the use of multi-potent stem cells for regenerative medicine. His development of new procedures based on clinical application of the most advanced basic science and biotechnology at the patient’s bedside attracts patients from all over the world. Slavin has written four books and more than 650 scientific publications and serves on many editorial boards and many national and international advisory boards. He has received many international awards in recognition of his excellence in basic science and clinical medicine, introducing new therapeutic concepts that paved the road for successful treatment of patients considered incurable by conventional medicine.
David Agus, professor of medicine and engineering at the USC's Keck School of Medicine, argues that cancer treatment is too focused on "germ theory", and fails to take into consideration that a cure might be different for every patient.